Presurgical Biomarker Performance in the Detection of Gleason Upgrading in Prostate Cancer.
作者信息
Wittig Kristina, Yamzon Johnathan L, Smith David D, Jeske Daniel R, Smith Steven S
机构信息
Division of Urology, Department of Surgery, City of Hope, Duarte, California.
Division of Biostatistics, Department of Information Sciences, City of Hope, Duarte, California.
出版信息
Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1643-1645. doi: 10.1158/1055-9965.EPI-16-0488. Epub 2016 Aug 19.
BACKGROUND
Gleason Score (GS) upgrading is generally considered a trigger for exit to definitive treatment during active surveillance (AS). Predicting the potential for GS upgrading would be of value in assessing AS eligibility.
METHODS
We assessed the performance of biomarkers in presurgical specimens of expressed prostatic secretion (EPS) in this setting.
RESULTS
Although EPS volume, total recovered RNA, and RNA expression biomarkers (TMPRSS2: ERG, PCA3, PSA) have been successful in both biopsy outcome prediction, and in the prediction of upstaging in active surveillance eligible patients, they were unable to predict upgrading in patients eligible for active surveillance under National Comprehensive Cancer Network guidelines.
CONCLUSIONS
These biomarkers do not improve the prediction of upgrading over indications from standard clinical parameters.
IMPACT
Additional biomarkers will be needed in this area. Cancer Epidemiol Biomarkers Prev; 25(12); 1643-5. ©2016 AACR.
Zotero 插件